These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 26927159

  • 1. Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
    Campadelli-Fiume G, Petrovic B, Leoni V, Gianni T, Avitabile E, Casiraghi C, Gatta V.
    Viruses; 2016 Feb 26; 8(3):63. PubMed ID: 26927159
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.
    Menotti L, Avitabile E, Gatta V, Malatesta P, Petrovic B, Campadelli-Fiume G.
    Viruses; 2018 Jun 30; 10(7):. PubMed ID: 29966356
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
    Leoni V, Gatta V, Palladini A, Nicoletti G, Ranieri D, Dall'Ora M, Grosso V, Rossi M, Alviano F, Bonsi L, Nanni P, Lollini PL, Campadelli-Fiume G.
    Oncotarget; 2015 Oct 27; 6(33):34774-87. PubMed ID: 26430966
    [Abstract] [Full Text] [Related]

  • 12. Rethinking herpes simplex virus: the way to oncolytic agents.
    Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L.
    Rev Med Virol; 2011 Jul 27; 21(4):213-26. PubMed ID: 21626603
    [Abstract] [Full Text] [Related]

  • 13. The molecular basis of herpesviruses as oncolytic agents.
    Menotti L, Campadelli-Fiume G, Nanni P, Lollini PL, De Giovanni C.
    Curr Pharm Biotechnol; 2012 Jul 27; 13(9):1795-803. PubMed ID: 21740356
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.
    Shibata T, Uchida H, Shiroyama T, Okubo Y, Suzuki T, Ikeda H, Yamaguchi M, Miyagawa Y, Fukuhara T, Cohen JB, Glorioso JC, Watabe T, Hamada H, Tahara H.
    Gene Ther; 2016 Jun 27; 23(6):479-88. PubMed ID: 26905369
    [Abstract] [Full Text] [Related]

  • 16. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.
    Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G.
    J Virol; 2008 Oct 27; 82(20):10153-61. PubMed ID: 18684832
    [Abstract] [Full Text] [Related]

  • 17. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.
    Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, Zaghini A, Nanni P, Lollini PL, Casiraghi C, Campadelli-Fiume G.
    PLoS Pathog; 2018 Aug 27; 14(8):e1007209. PubMed ID: 30080893
    [Abstract] [Full Text] [Related]

  • 18. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
    Tsuji T, Nakamori M, Iwahashi M, Nakamura M, Ojima T, Iida T, Katsuda M, Hayata K, Ino Y, Todo T, Yamaue H.
    Int J Cancer; 2013 Jan 15; 132(2):485-94. PubMed ID: 22729516
    [Abstract] [Full Text] [Related]

  • 19. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
    Conner J, Braidwood L, Brown SM.
    Gene Ther; 2008 Dec 15; 15(24):1579-92. PubMed ID: 18701918
    [Abstract] [Full Text] [Related]

  • 20. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
    Uchida H, Hamada H, Nakano K, Kwon H, Tahara H, Cohen JB, Glorioso JC.
    Curr Cancer Drug Targets; 2018 Dec 15; 18(2):162-170. PubMed ID: 28176649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.